Table 3.

Associations between CN expression, clinical parameters and overall survival

Clinical parameters	Overall survival (months)
	Total type				Clear-cell carcinoma				Serous carcinoma				Papillary serous cystadenocarcinoma
	N	Mean	95%CI	p-value	N	Mean	95%CI	p-value	N	Mean	95%CI	p-value	N	Mean	95%CI	p-value
CN
≦50	24	96.73	76.00, 117.46	0.53	7	73.57	53.15, 93.99	0.73	7	69.29	34.03, 104.54	0.03*	10	73.33	59.06, 87.61	0.27
>50	17	63.24	49.45, 77.02		10	69.8	52.34, 87.26		2	22.00	10.24, 33.76		5	59.4	39.98, 78.82
Age (years)
< 50	26	140.79	106.30, 175.28	0.30	10	79.56	65.43, 93.69	0.18	7	118.88	52.82, 184.93	0.63	9	73.44	60.56, 86.33	0.91
≧50	24	86.20	67.27, 105.12		9	60.40	40.08, 80.72		8	72.71	40.43, 105.00		7	63.00	44.19, 81.86
Pathological stage
I~II	29	160.80	133.60, 188.00	< 0.01*	9	87.56	81.19, 93.92	0.03*	10	143.50	91.66, 195.34	< 0.01*	10	70.20	56.49, 83.91	0.26
III~IV	20	53.05	40.27, 65.83		9	55.67	34.21, 77.12		5	31.80	24.86, 38.74		6	65.17	46.86, 83.47
Tumor size (mm3)
< 395	26	123.50	91.08, 155.92	0.71	5	66.60	40.40, 92.80	0.81	12	110.33	61.84, 158.82	0.67	9	71.33	57.58, 85.09	0.98
≧395	24	68.00	56.19, 79.81		14	70.50	55.05, 85.95		3	48.00	22.28, 73.72		7	65.71	47.24, 84.19
LN metastasis
No	31	158.09	131.28, 184.90	< 0.01*	11	82.91	72.21, 93.61	0.02*	10	143.50	91.66, 195.34	< 0.01*	10	70.20	56.49, 83.91	0.26
Yes	19	50.95	38.08, 63.82		8	51.00	28.58, 73.43		5	31.80	24.86, 38.74		6	65.17	46.86, 83.47
Distant metastasis
No	48	127.95	103.85, 152.05	0.88	18	82.46	76.09, 88.82	0.49	15	106.27	63.19, 149.34	─	15	69.53	57.31, 81.76	0.39
Yes	2	75.00	66.68, 83.32		1	81.00	81.00, 81.00		0	─	─		1	69.00	69.00, 69.00
Ascites
No	26	134.35	101.53, 167.16	0.59	10	65.50	49.72, 81.28	0.84	11	113.46	60.45, 166.46	0.65	5	80.40	74.09, 86.71	0.19
Yes	24	66.34	54.61, 78.06		9	70.56	50.00, 91.11		4	55.00	32.34, 77.66		11	63.64	48.48, 78.79
Chemotherapeutic response
No	2	66.00	38.28, 93.72	0.99	1	46.00	46.00, 46.00	0.27	0	─	─	─	1	86.00	86.00, 86.00	0.47
Yes	37	91.51	75.18, 107.84		15	70.60	55.21, 85.99		10	66.40	37.16, 95.64		12	85.75	78.54, 92.96
Chemotherapeutic resistance
No	21	125.89	110.57, 141.23	< 0.01*	5	88.56	82.19, 94.92	0.01*	5	123.00	87.94, 158.06	0.24	11	77.12	68.46, 85.77	0.02*
Yes	11	52.27	37.78, 66.76		5	49.00	26.58, 71.43		1	59.00	59.00, 59.00		5	49.60	27.15, 72.05
CA125 (U/ml)
< 324	24	120.68	85.63, 155.73	0.49	11	77.27	63.36, 91.19	0.41	5	113.89	55.42, 172.36	0.43	8	74.18	59.48, 88.87	0.56
≧324	24	71.67	61.36, 81.87		7	59.86	36.36, 83.36		9	50.40	29.89, 70.90		8	63.88	47.47, 80.28
CA19–9 (U/ml)
< 21.55	24	130.61	94.49, 166.73	0.75	8	81.25	63.37, 99.13	0.21	8	134.29	64.96, 203.61	0.22	8	76.88	67.98, 85.77	0.60
≧21.55	23	99.98	80.42, 119.54		9	64.56	47.29, 81.82		7	65.75	34.39, 97.11		7	59.00	37.42, 80.58
CA72–4 (U/ml)
< 7.89	25	164.61	134.70, 194.52	< 0.01*	8	86.56	80.19, 92.92	0.01*	9	134.56	76.93, 192.18	0.10	8	69.13	52.32, 85.93	0.26
≧7.89	24	56.17	45.78, 66.56		10	53.67	32.21, 75.12		6	42.83	29.35, 56.31		8	67.88	53.35, 82.40
AFP (ng/mL)
< 2.9	25	142.27	108.32, 176.22	0.32	7	73.00	55.03, 90.97	0.60	6	115.00	57.28, 172.72	0.54	12	81.75	74.54, 88.96	0.37
≧2.9	24	87.09	67.74, 106.44		11	66.57	48.66, 84.48		9	70.83	32.42, 109.25		4	64.01	50.29, 77.73
CEA (ng/mL)
< 1.48	24	141.13	106.79, 175.46	0.28	10	78.13	62.51, 93.74	0.45	8	132.43	61.69, 203.16	0.28	6	72.33	62.58, 82.09	0.95
≧1.48	24	85.70	65.99, 105.41		8	62.80	44.44, 81.16		7	66.63	36.26, 96.99		9	63.56	45.83, 81.28

Kaplan-Meier test using log rank; LN, lymph node; CA125, cancer antigen 125; CA19–9, cancer antigen 19–9; CA72–4, cancer antigen 72–4; AFP, alpha-fetoprotein; CEA, carcinoembryonic antigen; *p < 0.05